Data compiled by Redley Lamar · ChainSifter Intelligence
13Suppliers
4Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Intensity Therapeutics, Inc. (INTS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
21Total relationships
3Distinct source URLs
11High confidence
0.797Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Intensity Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CENTRAL-LABORATORIES
CENTRAL-LABORATORIES
90%
External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and …
CLINICAL-TRIAL-SITES
CLINICAL-TRIAL-SITES
90%
External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and …
CONTRACT-MANUFACTURING-ORGANIZATIONS
CONTRACT-MANUFACTURING-ORGANIZATIONS
90%
External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and …
CONTRACT-RESEARCH-ORGANIZATIONS
CONTRACT-RESEARCH-ORGANIZATIONS
90%
External costs consist primarily of payments to outside consultants, third-party CROs, CMOs, clinical trial sites and central laboratories in connection with the Company’s clinical manufacturing and …
SWISS-CANCER-INSTITUTE
SWISS-CANCER-INSTITUTE
80%
In October 2024, in collaboration with the Swiss Cancer Institute, formerly the Swiss Cancer Group for Clinical Cancer Research (SAKK), we initiated and dosed our first patient in a Phase 2 study
Reciprocal relationship from ATON graph: Reciprocal relationship from INTS graph: Reciprocal relationship from ATON graph: Reciprocal relationship from INTS graph: Reciprocal relationship from ATON g…
Reciprocal relationship from GILD graph: Reciprocal relationship from INTS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from INTS graph: Reciprocal relationship from GILD g…
n when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The government may assert that a claim that includes items o…
Reciprocal relationship from ORANY graph: Reciprocal relationship from INTS graph: ess and monitor the product’s safety and effectiveness after commercialization. FDA may also condition approval of a…
ess and monitor the product’s safety and effectiveness after commercialization. FDA may also condition approval of a drug product on the development and approval of a REMS. A REMS could include medic…
n when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The government may assert that a claim that includes items o…
Reciprocal relationship from REPL graph: Reciprocal relationship from INTS graph: Reciprocal relationship from REPL graph: Reciprocal relationship from INTS graph: Reciprocal relationship from REPL g…
Reciprocal relationship from SOHU graph: Reciprocal relationship from INTS graph: Reciprocal relationship from SOHU graph: . In November 2024, the FASB issued ASU No. 2024-03, Income Statement (Topic…
In 2019, as part of our IT-01 Study, we entered into a supply agreement with Merck to evaluate the combination of INT230-6 with Keytruda ® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with…
Reciprocal relationship from MRK graph: Reciprocal relationship from INTS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from INTS graph: Reciprocal relationship from MRK grap…
CO-LLC
CO-LLC
62%
n 2025 compared to zero in 2024. • Insurance decreased by $0.2 million due to the favorable directors and officers insurance renewal terms obtained in 2025 compared to the prior policy year. • Legal,…
THINKEQUITY-LLC
THINKEQUITY-LLC
62%
n 2025 compared to zero in 2024. • Insurance decreased by $0.2 million due to the favorable directors and officers insurance renewal terms obtained in 2025 compared to the prior policy year. • Legal,…
Intensity Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
INTS-DEBT-10308
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
INTS-DEBT-10307
Warrants outstanding: 159000
90%
xbrl warrant detail from xbrl 2023-12-31.
INTS-DEBT
Debt stack $102,000
90%
Market cache reports total debt of $102,000.
Intensity Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Intensity Therapeutics, Inc..
Intensity Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
INTS-OWNER-CORIENT-PRIVATE-WEALTH-LLC
Corient Private Wealth LLC
90%
13F overlay lists Corient Private Wealth LLC as top holder; 3 tracked holders.
Intensity Therapeutics, Inc. Extended Supply Chain Network
